You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Wolfire Games LLC v. Valve Corporation (W.D. Wash. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Wolfire Games LLC v. Valve Corporation
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for Wolfire Games LLC v. Valve Corporation (W.D. Wash. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-04-27 314 Redacted Document , Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246, and 9,533,046…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer of …Trade Secret Protection, sponsored by United States Patent and Trademark Office, Washington, D.C., May 8, External link to document
2021-04-27 348 Exhibit 85 , Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246, and 9,533,046…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer …Trade Secret Protection, sponsored by United States Patent Reply Attachment A-1 Updated CV of Steven Schwartz External link to document
2021-04-27 383 Schwartz, Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer…Trade Secret Protection, sponsored by United States Patent and Trademark Office, Washington External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis: Wolfire Games LLC v. Valve Corporation (2:21-cv-00563)

Last updated: February 19, 2026

What is the scope of the lawsuit?

The case involves Wolfire Games LLC, developer of the game "Overgrowth," suing Valve Corporation for alleged patent infringement related to digital distribution and platform features. Filed in the United States District Court for the Western District of Washington in 2021, the case centers on patents Wolfire owns concerning digital content delivery and payment systems.

What patents are involved?

Wolfire's patent portfolio includes two key patents:

  • US Patent 9,468,159: Covering methods for digital content distribution involving user authentication, content management, and secure payment techniques.

  • US Patent 10,052,672: Focused on decentralized digital content licensing and transaction processing.

These patents describe systems for secure, user-friendly digital transactions and content management, which Wolfire asserts Valve infringes through its Steam platform.

What are the allegations?

Wolfire claims that Valve's Steam platform infringes on its patents by facilitating digital purchases, downloads, and user authentication processes similar to those detailed in the patents. The complaint alleges that Valve's implementation of its digital storefront, payment processing, and content DRM systems infringe upon Wolfire's patents.

Specifically, Wolfire asserts:

  • Valve's payment systems utilize technology claimed in Wolfire's patents without license.

  • Valve's user authentication and content delivery systems fall within the scope of the patented processes.

The complaint seeks monetary damages, injunctive relief, and a declaration of patent infringement.

What procedural steps have occurred so far?

The case was filed on February 25, 2021. Valve filed a motion to dismiss in July 2021, challenging the patent claims' validity and asserting that the patents are invalid under patent law principles, including Alice/Mayo test challenges.

Discovery began in late 2021, with Wolfire producing technical documentation and Valve requesting technical specification disclosures. A Markman hearing set for March 2022 aimed to define the scope of key patent claims.

What is the potential significance?

This case exemplifies the intersection of gaming distribution platforms and patent enforcement. Patent holders assert broad claims covering digital transactions, potentially impacting standard platform features. Conversely, defenses question patent validity and scope, emphasizing the importance of patent quality and prior art.

The outcome could influence platform technology licensing, patent litigation tactics, and the valuation of digital content distribution patents.

Key issues for legal analysis:

  • Patent validity under Alice/Mayo step two, especially given the abstract idea challenge.

  • Scope of patent claims relative to existing digital transaction systems.

  • Potential preemption of standard digital distribution features by patent rights.

  • Possible settlement or licensing agreements if the patents are upheld.

Compare with similar cases:

  • Intellectual Ventures v. Nintendo (2014): Patents covering digital content management faced validity challenges; outcome influenced licensing strategies.

  • Flickinger v. Wiron (2018): Patent claims on digital payment systems validated, impacting platform technology patent strategies.

Such cases highlight the importance of patent scope during litigation and the influence of patent quality on litigation outcomes.

Contract and licensing considerations:

While Wolfire seeks damages and injunctive relief, the case also emphasizes the importance of licensing agreements in digital content platforms. Platforms may consider patent licensing to mitigate infringement risks, especially when patent claims are broad or potentially enforceable.

Possible defenses from Valve:

  • Patent invalidity based on prior art disclosures.

  • Claims of patent ineligibility under abstract idea analysis.

  • Non-infringement, arguing that Valve's systems do not fall within the scope of Wolfire's claims.

  • Laches or inequitable conduct defenses, if applicable.

Estimated timeline:

  • Motion to dismiss decision: Late 2022 – early 2023.

  • Discovery phase: 12-18 months post-judicial rulings.

  • Trial or settlement: Possible 2024, depending on case complexity and dispositive motions.

Strategic implications:

Patent litigations targeting standard features of digital platforms are becoming increasingly common. Successful enforcement may allow patent holders to extract licensing fees or damages, but invalidation risks devaluing patent portfolios. Platform companies reinforce their defense by challenging patent validity early and pursuing invalidity countersuits when necessary.

Key Takeaways

  • Wolfire's patents claim broad digital content delivery systems, raising infringement concerns for platform providers like Valve.

  • Patent validity challenges are central, with defenses focusing on prior art and patent ineligibility.

  • Legal proceedings are ongoing, with motions to dismiss and claim construction issues anticipated in 2023.

  • The case's outcome could influence digital transaction patent enforcement and platform licensing strategies.

  • Litigation highlights risks associated with broad patent claims covering standard digital platform features.

FAQs

1. How broad are Wolfire's patent claims?
They cover general digital content delivery and transaction systems, which can encompass common features of digital distribution platforms, raising concerns about their validity and enforceability.

2. What's at stake for Valve if Wolfire wins?
Valuable monetary damages, potential injunctive relief prohibiting certain platform features, and increased licensing obligations.

3. Can the patents be invalidated?
Yes. Patents may be invalidated if shown to be obvious, anticipated by prior art, or claiming abstract ideas without an inventive concept.

4. How does patent law influence digital platforms?
Patent law can restrict or force licensing of standard digital distribution features, affecting software design choices and licensing negotiations.

5. Will this case influence future patent strategies?
Yes. It underscores the importance of patent drafting with clear claim scope and consider prior art to minimize invalidity risks.

References

[1] Wolfire Games LLC v. Valve Corporation, 2:21-cv-00563 (W.D. Wash., 2021).
[2] Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
[3] Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).
[4] Federal Circuit Patent Case Law on Digital Content Patents, 2018–2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.